1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Human Papillomavirus Infections Global Clinical Trials Review, H1, 2015

Human Papillomavirus Infections Global Clinical Trials Review, H1, 2015

Summary

GlobalData's clinical trial report, “Human Papillomavirus Infections Global Clinical Trials Review, H1, 2015" provides an overview of Human Papillomavirus Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Human Papillomavirus Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Human Papillomavirus Infections Global Clinical Trials Review, H1, 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Human Papillomavirus Infections 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Human Papillomavirus Infections to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Human Papillomavirus Infections to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Human Papillomavirus Infections 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Human Papillomavirus Infections Therapeutics Clinical Trials 31
Prominent Drugs 32
Latest Clinical Trials News on Human Papillomavirus Infections 33
Jun 16, 2015: Genticel Receives FDA Clearance of IND Application for U.S. Phase 1 Clinical Trial of GTL001, Company's First-in-class HPV Therapeutic Vaccine Candidate 33
Apr 20, 2015: Genticel to Present Further Promising Pharmacology In-Vivo Results of Its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (ProCervix), at AACR Annual Meeting 2015 33
Clinical Trial Profiles 34
Clinical Trial Overview of Top Companies 34
GlaxoSmithKline Plc 34
Clinical Trial Overview of GlaxoSmithKline Plc 34
Merck and Co., Inc. 39
Clinical Trial Overview of Merck and Co., Inc. 39
Merck Sharp and Dohme Corp. 42
Clinical Trial Overview of Merck Sharp and Dohme Corp. 42
Valeant Pharmaceuticals International, Inc. 45
Clinical Trial Overview of Valeant Pharmaceuticals International, Inc. 45
Medicis Pharmaceutical Corporation 46
Clinical Trial Overview of Medicis Pharmaceutical Corporation 46
Genticel S.A. 47
Clinical Trial Overview of Genticel S.A. 47
Nestle S.A. 48
Clinical Trial Overview of Nestle S.A. 48
BioMAS Ltd. 49
Clinical Trial Overview of BioMAS Ltd. 49
AstraZeneca Plc 50
Clinical Trial Overview of AstraZeneca Plc 50
Akela Pharma Inc. (Inactive) 51
Clinical Trial Overview of Akela Pharma Inc. (Inactive) 51
Clinical Trial Overview of Top Institutes / Government 52
The National Institute of Allergy and Infectious Diseases 52
Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 52
National Cancer Institute 53
Clinical Trial Overview of National Cancer Institute 53
AIDS Malignancy Clinical Trials Consortium 55
Clinical Trial Overview of AIDS Malignancy Clinical Trials Consortium 55
Leiden University Medical Center 56
Clinical Trial Overview of Leiden University Medical Center 56
Medical University of Vienna 57
Clinical Trial Overview of Medical University of Vienna 57
Dana-Farber Cancer Institute, Inc. 58
Clinical Trial Overview of Dana-Farber Cancer Institute, Inc. 58
Duke University 59
Clinical Trial Overview of Duke University 59
Second Affiliated Hospital of Shanxi Medical University 60
Clinical Trial Overview of Second Affiliated Hospital of Shanxi Medical University 60
Shiraz University of Medical Sciences 61
Clinical Trial Overview of Shiraz University of Medical Sciences 61
The Johns Hopkins University 62
Clinical Trial Overview of The Johns Hopkins University 62
Five Key Clinical Profiles 63
Appendix 117
Abbreviations 117
Definitions 117
Research Methodology 118
Secondary Research 118
About GlobalData 119
Contact Us 119
Disclaimer 119
Source 120

List of Tables
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials by Region, 2015* 7
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Human Papillomavirus Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Human Papillomavirus Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Human Papillomavirus Infections Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Human Papillomavirus Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015* 13
Human Papillomavirus Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015* 14
Proportion of Human Papillomavirus Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2015* 15
Human Papillomavirus Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Human Papillomavirus Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Human Papillomavirus Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2015* 18
Human Papillomavirus Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Human Papillomavirus Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Human Papillomavirus Infections Therapeutics, Global, Suspended Clinical Trials, 2015* 25
Human Papillomavirus Infections Therapeutics, Global, Withdrawn Clinical Trials, 2015* 26
Human Papillomavirus Infections Therapeutics, Global, Terminated Clinical Trials, 2015* 27
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28
Human Papillomavirus Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 29
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline Plc, 2015* 34
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2015* 39
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck Sharp and Dohme Corp., 2015* 42
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Valeant Pharmaceuticals International, Inc., 2015* 45
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Medicis Pharmaceutical Corporation, 2015* 46
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Genticel S.A., 2015* 47
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Nestle S.A., 2015* 48
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by BioMAS Ltd., 2015* 49
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca Plc, 2015* 50
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Akela Pharma Inc. (Inactive), 2015* 51
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2015* 52
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 53
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AIDS Malignancy Clinical Trials Consortium, 2015* 55
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2015* 56
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2015* 57
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Dana-Farber Cancer Institute, Inc., 2015* 58
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2015* 59
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Second Affiliated Hospital of Shanxi Medical University, 2015* 60
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Shiraz University of Medical Sciences, 2015* 61
Human Papillomavirus Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The Johns Hopkins University, 2015* 62

List of Figures
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Human Papillomavirus Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Human Papillomavirus Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Human Papillomavirus Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Human Papillomavirus Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015* 13
Human Papillomavirus Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015* 14
Proportion of Human Papillomavirus Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2015* 15
Human Papillomavirus Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Human Papillomavirus Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Human Papillomavirus Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2015* 18
Human Papillomavirus Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Human Papillomavirus Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Human Papillomavirus Infections Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28
Human Papillomavirus Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 29
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31
Human Papillomavirus Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32
GlobalData Methodology 118

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.